Ondine Biomedical Inc
LSE:OBI
Ondine Biomedical Inc
Capital Expenditures
Ondine Biomedical Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Capital Expenditures
-CA$177k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Titan Medical Inc
TSX:TMD
|
Capital Expenditures
-$116k
|
CAGR 3-Years
48%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-4%
|
|
|
Profound Medical Corp
TSX:PRN
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanalysis Scientific Corp
XTSX:NSCI
|
Capital Expenditures
-CA$4.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Capital Expenditures
-CA$20k
|
CAGR 3-Years
42%
|
CAGR 5-Years
48%
|
CAGR 10-Years
16%
|
|
|
MedMira Inc
XTSX:MIR
|
Capital Expenditures
-CA$2.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
31%
|
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
What is Ondine Biomedical Inc's Capital Expenditures?
Capital Expenditures
-177k
CAD
Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Capital Expenditures amounts to -177k CAD.
What is Ondine Biomedical Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 1Y
43%
Over the last year, the Capital Expenditures growth was 43%.
You don't have any saved screeners yet